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Background: Functional TRIB3 Q84R polymorphism has been associated with insulin resistance. Obestatin,
improving insulin resistance, exerts obscure effects on metabolic syndrome (MetS) and carotid atherosclerosis. Aims
to investigate whether the prevalent TRIB3 Q84R polymorphism has profound implications for alterations of serum
obestatin and what effect obestatin exerts on carotid atherosclerosis.
Methods: A total of 518 unrelated Chinese subjects consisted of control (n = 258) and MetS (n = 260) groups.
Clinical and biochemical characteristics were collected. The level of serum obestatin was measured. Genotype the
functional TRIB3 Q84R polymorphism. All subjects underwent ultrasonography to determine carotid intima-media
thickness (IMT).
Results: Serum obestatin was significantly decreased in MetS as compared with the control group (P = 0.042).
Among the MetS group participants possessing RR84 genotype had significantly lower levels of serum obestatin
than those with QQ84 or QR84 genotypes (P = 0.008, P = 0.043) with similar significant difference among the control
group. Factorial analyses showed statistically significant interactions between MetS and RR84 genotype (P = 0.009
for interaction for obestatin). On correlation analysis, obestatin correlated negatively with homeostasis model
assessment insulin resistance (r = -0.163, P = 0.010) and IMT (r = -0.256, P = 0.011). On partial analyses, obestatin
negatively correlated with IMT(r = -0.259, P = 0.024) after controlling for the confounding factors.
Conclusion: MetS individuals with TRIB3 RR84 genotype demonstrated further decreased serum obestatin.
Decreased serum obestatin might in part exacerbate insulin resistance and carotid atherosclerosis.
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The existence of metabolic syndrome (MetS) implies a
shift from a pathophysiology concept based on metabolic
abnormalities resulting from an insulin-resistant state to
an epidemiological construct based on abdominal obes-
ity and crude correlates of the features of insulin resist-
ance. Excessive circulating adipocytokines might provide
pathways linking abdominal obesity to insulin resistance,* Correspondence: doc260@163.com
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reproduction in any medium, provided the orwhich has led several groups to try to identify secreted
products derived specifically from this depot. Obestatin
[1], reducing food intake, body weight gain, gastric
emptying, and jejunal motility, has been demonstrated
to be involved in insulin resistance and metabolic dys-
functions. The functional profiles of obestatin reported
in the past studies would suggest a regulator of adipo-
cyte metabolism by promoting adipogenesis in an auto-
crine/paracrine manner [2,3], which pointing to a
putative role in the pathogenesis of metabolic syndrome.
However, at present the pathophysiological role of obes-
tatin in MetS remains unknown.. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Demographic characteristics of the studied
population
Characteristics Control group MetS group P
(n = 258) (n = 260)
Sex (male/female) 155/103 159/101 0.802
Age (years) 54 ± 8 55 ± 9 0.182
WC (cm) 82.08 ± 7.69 97.42 ± 9.44 <0.001
SBP (mmHg) 114.90 ± 10.85 151.29 ± 22.82 <0.001
DBP (mmHg) 75.03 ± 7.34 93.47 ± 13.70 <0.001
TG (mmol/L) 1.02 ± 0.40 2.32 ± 1.30 <0.001
HDL-C (mmol/L) 1.56 ± 0.36 1.22 ± 0.29 <0.001
FBG (mmol/L) 4.83 ± 0.60 6.61 ± 2.48 <0.001
Insulin (μU/mL) 10.63 ± 4.73 20.78 ± 11.20 <0.001
Log(Obestatin) 109.65 ± 14.79 95.50 ± 13.80 <0.001
Data are means ± SD for normally-distributed variables.
Abbreviations: MetS, metabolic syndrome; WC, Waist circumference; SBP,
systolic blood pressure; DBP, diastolic blood pressure; TG, triglycerides; HDL-C,
high-density lipoprotein cholesterol; FBG, fasting blood glucose.
Table 2 Genotype and allele frequency of TRIB3 Q84R
polymorphism in subjects with and without MetS
QQ84 QR84 RR84 Q84 R84
Control group 168 70 20 406 110
MetS group 155 79 26 389 131
Abbreviations: MetS, metabolic syndrome.
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revealed that obestatin regulates adipocyte function and
protects against diet-induced insulin resistance and in-
flammation [3]. As previously reported, obestatin is
decreased in obese subjects [4]. However, whether
decreased obestatin ameliorates or deteriorates insulin
resistance remains obscure. Furthermore, what effects
obestatin exerts upon carotid atherosclerosis remains
unknown.
TRIB3 (a mammalian tribbles homolog, also known as
TRIB3/NIPK, gene ID 57761), has been reported by
most studies [5,6], although not all studies [7], impli-
cated in the regulation of insulin signal transduction by
binding to and inhibiting Akt phosphorylation and to
play a role in insulin resistance [5,6]. Furthermore, it has
been demonstrated that the TRIB3 gene, especially the
R84 variant, could help identify individuals at risk for in-
sulin resistance and carotid atherosclerosis risk by deter-
mining carotid intima-media thickness (IMT) [8]. As
mentioned above, obestatin might go down with MetS,
the key culprit of which is insulin resistance. Therefore,
obestatin might be involved in MetS. However, whether
the prevalent TRIB3 missense Q84R polymorphism has
profound implications for alterations of serum obestatin
and what effect obestatin exerts remain to be established.
In the present study, we aimed to investigate the role
of obestatin in MetS and carotid atherosclerosis under
the background of TRIB3 Q84R polymorphism by case-
control study.
Materials and methods
A total of 518 unrelated homogenous Chinese subjects
between the ages of 30 and 77 years were recruited
from the Yantai Municipal Laiyang Central Hospital ofShandong: 260 subjects [159 men; mean age 55 ± 9 years]
with MetS, defined according to the 2005 criteria of the
International Diabetes Federation; 258 subjects (con-
trols) [155 men; mean age 54 ± 8 years] without cardio-
vascular diseases or elevated fasting glucose (fasting
plasma glucose ≥ 5.6 mmol/L) and with waist circumfer-
ence less than 90 cm for men and 80 cm for women, de-
fining central obesity, conducted from September 20,
2008 to June 2, 2011. Written informed consent was
obtained from all subjects before enrollment in the
study, and procedures were approved by the ethics com-
mittees of Yantai Municipal Laiyang Central Hospital of
Shandong and followed the Helsinki Declaration criteria.
Subjects were advised to refrain from strenuous phys-
ical activity, smoking, eating and drinking for at least
12 h before the screening visit. Screening included the
completion of standardized questionnaires collecting
personal information and the collection of data on age,
sex, personal medical history, and history of coronary
heart disease, hypertension, dyslipidemia, and diabetes.
Systolic blood pressure (SBP) and diastolic blood pres-
sure (DBP) were measured twice in the right arm then
averaged for subjects who had been resting for at least
10 min in a comfortable position. Waist circumference
was measured at the midpoint between the iliac crest
and the lower rib margin and hip circumference around
the maximum circumference of the buttocks posteriorly
and the symphysis pubis anteriorly.
Laboratory measurements
After blood samples were taken, plasma preserved with
EDTA and serum were separated immediately by centri-
fugation at 2500 g for 10 min. Glucose measurements
involved the glucose oxidase method. Total cholesterol
and total triglyceride levels were determined by enzym-
atic methods. HDL-C was measured in the supernatant
after precipitation of apo B-containing lipoproteins with
use of phosphotungstic acid and magnesium chloride.
LDL-C level was calculated by use of the Friedewald for-
mula. LDL-C was not calculated for individuals with tri-
glyceride level >4.5 mmol/L. Serum concentration of
insulin was determined by use of a radioimmunometric
assay kit (Dongya Ltd, Beijing). Intra- and interassay
coefficients of variation for insulin were 10% and 15%,
respectively; no cross-reactivity was observed between
insulin and proinsulin. Insulin resistance was assessed
from glucose and insulin concentrations by the use of
Table 3 Comparison of levels of serum obestatin by TRIB3 Q84R genotype
QQ84 QR84 RR84 P for ANOVA
Control group
(n = 258)
151.36 ± 11.75 102.33 ± 14.45** 95.50 ± 17.39**† <0.001
MetS group
(n = 260)
112.20 ± 14.79 100.01 ± 16.98** 70.79 ± 19.50**† <0.001
Data are means ± SD. ** P < 0.01 vs QQ84 genotype, † P < 0.05 vs QR84 genotype.
Abbreviations are as in Table 1.
Table 4 Multivariable models of the relationship of
obestatin with carotid atherosclerosis, adjusted for






Abbreviations are as in Table 1.
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which equals to fasting blood glucose multiplied by fast-
ing insulin then divided by 22.5 [9]. Details about the
anthropometric and biochemical parameters refer to
Table 1.
Serum obestatin assay
Serum obestatin was measured by a commercially avail-
able RIA kit (Phoenix Pharmaceuticals Inc., Mountain
View, CA, USA) following the manufacturer’s instruc-
tion. Samples were measured in duplicate in a single ex-
periment. The intra- and interassay coefficients of
variance of this kit are < 5% and < 14%, respectively.
Genotyping
Genomic DNA was prepared from blood leukocytes by
established methods. Genotyping of the TRIB3 R84
variant involved the RFLP-PCR method with the pri-
mers 50- GGC CAC CAA GCA GTC TCAC -30 (forward)
and 50- CGC CCA TGA TCC CTA AGT TC -30 (reverse).
PCR conditions and protocols were as described by Pru-
dente et al. [10]. Screening was performed by adding 1 unit
of MspI restriction enzyme (Takara Biotechnology(Dalian)
Co.,Ltd) into 15 μL of PCR product. After 2-h incubation at
37°C, products were loaded onto 1.5% agarose gel and
visualized by staining with ethidium bromide. For genotyp-
ing, positive and negative controls (known sequences after
sequencing) were used, and the rate of genotyping success
for the SNP was >99%. (Additional file 1: Figure S1).
Echocardiography
All subjects underwent echocardiographic examination
with a commercially available ultrasound machine (Vivid
7 dimension; General Electric Medical Systems, Horten,
Norway) equipped with a 2.5 MHz variable-frequency
scanner as reported [8].
Statistical analysis
The Kolmogorov-Smirnov test was used to test for nor-
mal distribution. Normally distributed data are presented
as means ± SD, and non-normally distributed data are
presented as medians (quartile range). Non-normally
distributed variables were given a log-transformation if
necessary. Continuous variables were compared between
groups by unpaired Student’s t test or Mann-Whitney Utest and among groups by one-way ANOVA with post-
hoc LSD t test when appropriate. The chi-square test
was used to analyze the associations between categorical
variables and for Hardy-Weinberg equilibrium. The cor-
relation between 2 variables was assessed by Pearson or
Spearman correlation coefficient analysis. After control-
ling for covariates, bivariate correlations underwent
partial correlation analysis. Next, multivariable models
were constructed to study the effects of obestatin on
heart, with other study variables taken into account as
covariates. A P value <0.05 was considered significant
whether obtained from a one-tailed or two-tailed test of




Genotyping was successful in 518 subjects. The
TRIB3 Q84R polymorphism genotypes were in Hardy-
Weinberg equilibrium (Table 2). Demographic character-
istics of the study population are in Table 1. Serum
obestatin was significantly decreased in MetS as com-
pared with the control group. Demographic characteris-
tics among different genotype subgroups are provided in
Additional file 2: Tables S1 and S2.
Effects of TRIB3 polymorphism on serum obestatin
Among the control group, the obestatin concentrations
of QQ84, QR84 and RR84 were 151.36 ± 11.75, 102.33 ±
14.45 and 95.50 ± 17.39, respectively; significant differ-
ences were observed between groups. Among the MetS
group, participants possessing RR84 genotype had sig-
nificantly lower levels of serum obestatin than those with
QQ84 or QR84 genotypes (Table 3). Furthermore, MetS
patients possessing RR84 genotype had even lower levels
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(70.79 ± 19.50 vs 95.50 ± 17.39, P = 0.0001). The similar
results in QQ84 genotypes.
Association of decreased obestatin with carotid
atherosclerosis in metabolic syndrome patients
What effect decreased obestatin exerts on carotid artery
remains an open question. Correlation analysis showed
that obestatin had a negative correlation with TC and
LDL (r = -0.202, P = 0.018; r = -0.205, P = 0.016; respect-
ively). Obestatin was negatively correlated with carotid
IMT (r = -0.256, P = 0.011).
To get further insight into the association of serum
obestatin with carotid IMT in subjects with MetS, partial
analyses were performed. On partial analyses, obestatin
was negatively correlated with carotid IMT (r = -0.259,
P = 0.024) after controlling for sex, age, SBP, DBP, waist
circumference (WC), triglycerides, HDL-C, LDL-C, fast-
ing blood glucose (FBG), insulin and smoking.
Furthermore, the factors with statistically significant
associations with carotid IMT in the multivariable model
were age (β = 0.319, P = 0.001) and obestatin (β = -0.294,
P = 0.003, Table 4).
Discussion
To the best of our knowledge, this is the first study that
aims to elucidate the interplay between MetS, TRIB3
polymorphism and obestatin. In the present study TRIB3
RR84 genotype with MetS saw further decreased obesta-
tin. Furthermore, lowered obestatin might play an inde-
pendent role in carotid atherosclerosis.
TRIB3 polymorphism and obestatin
TRIB3 is implicated in the regulation of insulin signal
transduction [5] by binding to serine-threonine kinase
PKB/Akt and blocking its activation. TRIB3, thus, is
speculated to contribute to insulin resistance. Of note, a
progressive reduction of insulin-induced Ser473 Akt
phosphorylation was observed from untransfected con-
trol to Q84- and R84-expressing HepG2 cells with no
changes of Akt protein expression [10]. However, obes-
tatin enhanced glucose uptake in either the absence or
presence of insulin, promoted GLUT4 translocation, and
increased Akt phosphorylation, therefore reducing insu-
lin resistance [3]. As mentioned above, since TRIB3
induces insulin resistance which would be reversed in
part by obestatin, an important question has been
whether the TRIB3 polymorphism would determine the
level of serum obestatin.
Our results indicated that TRIB3 RR84 variant inter-
acts significantly with MetS on the level of serum obes-
tatin. As reported previously [4], obese subjects had
significantly lower levels of obestatin. However, no geno-
type of the TRIB3 altered the level of serum obestatinamong the control group. Further factorial analyses
showed that TRIB3 RR84 variant will decrease the level
of serum obestatin only in subjects with MetS.
In addition, it is important to acknowledge that only
homozygous TRIB3 RR84 variant could decrease the
level of serum obestatin in MetS individuals while het-
erozygous TRIB3 QR84 or homozygous TRIB3 QQ84
variants have no such, which suggested that here Q84 al-
lele is dominant with R84 allele recessive.
Obestatin and carotid artery in metabolic syndrome
Most intriguing of all, our results showed that serum
obestatin correlates inversely with IMT independent of
the other potential affecting factors, which suggested
that obestatin might have a bad effect on carotid athero-
sclerosis, otherwise obestatin may be a biomarker.
Limitation
Despite intriguing findings, the present results require
confirmation by a prospective population study, since
the MetS cohort was not all made up of newly diagnosed
subjects. However, this study provides new insights into
the potential associations of decreased obestatin with
TRIB3 Q84R polymorphism, MetS and carotid athero-
sclerosis. In fact, without the foundation provided by the
present study, the ensuing prospective population study
could not be implemented.
Conclusion
In conclusion, our results confirmed that serum obesta-
tin decreases with MetS, but further decreases due to
TRIB3 RR84 genotype. Incremental serum obestatin
might in part protect against carotid atherosclerosis.
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